Abbott Laboratories (NYSE: ABT) announced plans to separate its Nutrition business into an independent publicly traded company, creating a focused global leader in the rapidly expanding healthy nutrition market with approximately USD 8.5 billion in annual sales and a portfolio of iconic brands. Daniel Salvadori, Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products at Abbott, will become Chief Executive Officer of the new Nutrition company. The separation is expected to be completed by the end of 2027.
Transaction Snapshot
| Item | Detail |
|---|---|
| Announcing Company | Abbott Laboratories (NYSE: ABT) |
| Transaction Type | Separation of the Nutrition business into an independent publicly traded company |
| New Company Revenue Base | Approximately USD 8.5 billion in annual sales |
| Appointed CEO | Daniel Salvadori – EVP & Group President, Established Pharmaceuticals and Nutritional Products, Abbott |
| Workforce | Approximately 16,000 employees |
| Manufacturing Footprint | 14 manufacturing sites |
| Geographic Reach | Scale across both developed and emerging markets |
| Expected Completion | By end of 2027 |
| Separation Structure / Valuation | Not disclosed |
New Company Profile
- Positioning: A global leader in healthy nutrition, with the scale and brand equity to compete across the full nutrition value chain.
- Portfolio: A portfolio of iconic brands spanning the healthy nutrition category (individual brand allocations not itemized in the announcement).
- Leadership: Daniel Salvadori moves from Abbott’s Established Pharmaceuticals and Nutritional Products group to lead the new company as CEO, ensuring continuity of strategy and operations.
- Operational Scale: Approximately USD 8.5 billion in annual sales, ~16,000 employees, and 14 manufacturing sites from day one.
- Market Footprint: Established presence in both developed and emerging markets, enabling dual exposure to premium wellness demand and fast‑growing middle‑class nutrition consumption.
Strategic Rationale – Consumer Health & Nutrition Trends
- Independence: As a standalone public company, the Nutrition business can fully capitalize on consumer health and nutrition trends with a dedicated capital‑allocation and growth strategy.
- Demand Drivers: The company targets high‑growth consumer priorities including metabolic health, disease prevention, and wellness – segments where science‑based nutrition brands hold structural advantages.
- Market Context: The healthy nutrition market is rapidly expanding, supported by aging populations, rising preventive‑health awareness, and growing demand for medical and everyday nutrition products worldwide.
Market Impact & Outlook
- Pure‑Play Nutrition Leader: The separation creates one of the largest pure‑play publicly traded nutrition companies, giving investors direct exposure to a category typically housed inside diversified healthcare conglomerates.
- Scale Advantage: With ~16,000 employees and 14 manufacturing sites across developed and emerging markets, the new company retains Abbott‑grade manufacturing and R&D depth while gaining strategic focus.
- Abbott Portfolio Focus: Following the separation, Abbott’s remaining healthcare businesses – including diagnostics, medical devices, and established pharmaceuticals – will stay with the company; financial terms and post‑separation structure were not disclosed.
- Execution Timeline: Completion is targeted by the end of 2027; listing venue, share distribution mechanics, and brand‑level portfolio splits remain not yet disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the proposed separation of Abbott’s Nutrition business, including the anticipated structure, leadership, scale, benefits, and the expected completion timeline by the end of 2027. Actual outcomes may differ materially due to risks including regulatory approvals, market conditions, execution of the separation, and changes in strategic plans. No assurance is given that the transaction will be completed on the anticipated terms or timetable.-Fineline Info & Tech
